Iontophoretic delivery of apomorphine I: In vitro optimization and validation

Pharmaceutical Research

Volumn 14, Issue 12, 1997, Pages 1798-1803

  Van Der Geest, Ronald ^a,b   Danhof, Meindert ^a   Boddé, Harry E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Apomorphine; Human skin; In vitro in vivo correlation; Iontophoresis; Parkinson's disease; Skin metabolism

Indexed keywords

APOCODEINE; APOMORPHINE; DRUG METABOLITE;

ARTICLE; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; ELECTRIC CURRENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN TISSUE; IN VITRO STUDY; IONIC STRENGTH; IONTOPHORESIS; PRIORITY JOURNAL; SKIN; TEMPERATURE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031422128     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012100417645     Document Type: Article

References (25)

1. M. Danhof, J. W. Mandema, A. Hoogerkamp, and R. A. Mathôt. Eur. J. Drug Metab. Pharmacokinet. 18:41-47 (1993).
2. R. J. Hardie, A. J. Lees, and G. M. Stern. Brain 107:487-50 (1984).
3. T. van Laar, R. van der Geest, M. Danhof, H. E. Boddé, P. H. Goossens, and R. A. C. Roos. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin. Neuropharmacol. (in press).
4. A. J. Lees. Fundam. Clin. Pharmacol. 7:121-128 (1993).
5. J. P. Frankel, A. J. Lees, P. A. Kempster, and G. M. Stern. J. Neurol. Neurosurg. Psychiatry 53:96-101 (1990).
6. S. T. Gancher, J. G. Nutt, and W. R. Woodward. Mov. Disord. 6:212-216 (1991).
7. F. Durif, E. Beyssac, F. Coudoré, M. Paire, A. Eschalier, M. Aiache, and J. Lavarenne. Clin. Neuropharmacol. 17:445-453 (1994).
8. B. H. Sage. Iontophoresis. In E. W. Smith and H. I. Maibach (eds.), Percutaneous Penetration Enhancers, CRC Press, Boca Raton, 1995, pp. 351-368.
9. N. H. Yoshida and M. S. Roberts. Adv. Dr. Del. Rev. 9:239-264 (1992).
10. P. G. Green. J. Control. Rel. 41:33-48 (1996).
11. R. van der Geest, M. Danhof, and H. E. Boddé. Validation and testing of a new iontophoretic continuous flow through transport cell. J. Control. Rel. (1997) in press.
12. T. van Laar, J. J. van Hilten, C. Neef, A. W. F. Rutgers, S. Pavel, and J. A. Bruyn. Allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease are caused by EDTA: A histological study. (submitted).
13. R. van der Geest, P. Kruger, J. M. Gubbens-Stibbe, T. van Laar T, H. E. Boddé, and M. Danhof. Assay of R-apomorphine, S-apomorphine, apocodeine and isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. (1997) in press.
14. P. G. Green, R. S. Hinz, A. Kim, F. C. Szoka, and R. H. Guy. Pharm. Res. 8:1121-1127 (1991).
15. N. M. Volpato, P. Santi, and P. Colombo. Pharm. Res. 12:1623-1627 (1995).
16. V. Préat and S. Thysman. Int. J. Pharm. 96:189-196 (1993).
17. D. F. Hager, M. J. Laubach, J. W. Sharkey, and J. R. J. Control. Rel. 23:175-182 (1993).
18. R. van der Geest, T. van Laar, P. P. Kruger, J. M. Gubbens-Stibbe, H. E. Boddé, R. A. C. Roos, and M. Danhof. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. (submitted)
19. R. V. Padmanabhan, J. B. Phipps, G. A. Lattin, and R. J. Sawchuk. J. Control. Rel. 11:123-135 (1990).
20. M. B. Delgado-Charro and R. H. Guy. Pharm. Res. 11:929-935 (1994).
21. A. J. Hoogstraate, V. Srinivasan, S. M. Sims, and W. I. Higuchi. J. Control. Rel. 31:41-47 (1994).
22. J. E. Sanderson, S. Riel, and R. Dixon. J. Pharm. Sci. 78:361-364 (1989).
23. L. Wearley, J-C. Liu, and Y. W. Chien. J. Control. Rel. 8:237-250 (1989).
24. J. B. Phipps and J. R. Gyory. Adv. Dr. Del. Rev. 9:137-176 (1992).
25. I. H. Patel and R. H. Levy. J. Pharmacokin. Biopharm. 2:337-346 (1974).